AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24457893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental sealants (polyacid-modified compomer, flowable composite)
Number of subjects: 534
Study 22147460 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (2, 6, or 10 mg/kg)
Number of subjects: 46
Study 22147460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 20121768 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/formoterol fixed combination (BDP/FF)
Number of subjects: 0
Study 20121768 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate + formoterol delivered as separate inhalers (BDP + FF)
Number of subjects: 0
Study 18515507 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cefotetan or cefoxitin)
Number of subjects: 147
Study 18515507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 15937676 — intervention group
Group type: COMPARATOR
Intervention: Video group (one-time oral instruction by a physiotherapist and issued a video for home exercise)
Number of subjects: 90
Study 15937676 — intervention group
Group type: EXPERIMENTAL
Intervention: Café group (video regimen with three café meetings with other fusion-operated patients)
Number of subjects: 90
Study 15937676 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (exercise therapy; physiotherapist-guided; two times a week for 8 weeks)
Number of subjects: 90
Study 14654501 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promoting Schools (HPS) program
Number of subjects: 1852
Study 14654501 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1852
Study 10816228 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin
Number of subjects: 173
Study 10816228 — intervention group
Group type: COMPARATOR
Intervention: Control ointment (polysporin)
Number of subjects: 173
Study 8871001 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous chemotherapy with the 3M regimen (mitoxantrone, methotrexate and Mitomycin‐C) during radiotherapy (CRT)
Number of subjects: 197
Study 8871001 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous chemotherapy with the 3M regimen (CRT)
Number of subjects: 197
Study 8871001 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RTO)
Number of subjects: 197
Study 1728624 — intervention group
Group type: EXPERIMENTAL
Intervention: Predetermined meal three times daily (including cottage cheese, apple sauce, vanilla ice cream, and other selected foods)
Number of subjects: 19
Study 1728624 — intervention group
Group type: COMPARATOR
Intervention: Control group selected their own meal
Number of subjects: 19
Study 6426289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (2.1 mg/hour intravenously for 48 hours)
Number of subjects: 21
Study 6426289 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific therapy)
Number of subjects: 21
Study 29343510 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 0
Study 27552545 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.67 mg/m2 · d)
Number of subjects: 27
Study 27552545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24396050 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: smart phone with applications to guide interview, report data, show motivational video, and offer appointment for women with an abnormal CBE.
Number of subjects: 22337
Study 24396050 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: smart phone/applications identical to Arm A plus CHW had training in 'patient navigation'.
Number of subjects: 22337
Study 24396050 — intervention group
Group type: COMPARATOR
Intervention: Control Arm C: no smart phone; same interview recorded on paper.
Number of subjects: 22337
Study 22179300 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training group (1 hour training session on needling and proper hand‐eye coordination)
Number of subjects: 20
Study 22179300 — intervention group
Group type: COMPARATOR
Intervention: Conventional training group (4 didactic lectures on PNBs with ultrasound guidance)
Number of subjects: 20
Study 20647170 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155 U-195 U)
Number of subjects: 679
Study 20647170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 679
Study 18586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-based, reciprocal affected leg locomotor training protocol using the NuStep apparatus
Number of subjects: 7
Study 18586812 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme (HEP) consisting of self-supervised practice with fractionated joint movements of the lower limb
Number of subjects: 7
Study 16222518 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 25
Study 16222518 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced antilipolysis and lipogenesis
Number of subjects: 25
Study 16222518 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 25
Study 12020484 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization with CO(2) laser (TMR)
Number of subjects: 100
Study 12020484 — intervention group
Group type: COMPARATOR
Intervention: Continued medical treatment
Number of subjects: 100
Study 10468684 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg, amoxycillin 1 g, clarithromycin 500 mg (RAC)
Number of subjects: 398
Study 10468684 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg, metronidazole 400 mg, clarithromycin 500 mg (RMC)
Number of subjects: 398
Study 10468684 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg, metronidazole 400 mg, tetracycline 1 g (RMT)
Number of subjects: 398
Study 10468684 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg plus clarithromycin 500 mg for 2 weeks (RC-2)
Number of subjects: 398
Study 8522636 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril (7.5 mg and 15 mg once daily)
Number of subjects: 178
Study 8522636 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (180 mg and 240 mg once daily)
Number of subjects: 178
Study 1964898 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned baked beans (6 cans of 440 g per week)
Number of subjects: 20
Study 1964898 — intervention group
Group type: COMPARATOR
Intervention: Canned spaghetti (control)
Number of subjects: 20
Study 7457945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate administered intramuscularly at 0.006 mg/kg
Number of subjects: 0
Study 7457945 — intervention group
Group type: COMPARATOR
Intervention: Morphine chlorhydrate administered at 0.150 mg/kg
Number of subjects: 0
Study 31677033 — intervention group
Group type: EXPERIMENTAL
Intervention: d3RP‐NF2 program (8 week mind‐body resiliency program)
Number of subjects: 0
Study 31677033 — intervention group
Group type: EXPERIMENTAL
Intervention: d3RP‐NF2 program
Number of subjects: 0
Study 31677033 — intervention group
Group type: COMPARATOR
Intervention: dHEP‐NF2 (health education control)
Number of subjects: 0
Study 27655223 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT plus 50 mg veliparib BID (n=103)
Number of subjects: 307
Study 27655223 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT plus 200 mg veliparib BID (n=102)
Number of subjects: 307
Study 27655223 — intervention group
Group type: COMPARATOR
Intervention: WBRT plus placebo BID (n=102)
Number of subjects: 307
Study 27655223 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 307
Study 25872665 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingui external lotion
Number of subjects: 168
Study 25872665 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 168
Study 24064726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread and butter with boiled spinach
Number of subjects: 24
Study 24064726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread and butter meal
Number of subjects: 24
Study 24064726 — intervention group
Group type: COMPARATOR
Intervention: Bread meal
Number of subjects: 24
Study 22108480 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithromboembolic stockings, worn 24h/day
Number of subjects: 201
Study 22108480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 201
Study 19778662 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapies
Number of subjects: 0
Study 19778662 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of inflammatory biomarkers (e.g., CRP, interleukin-6)
Number of subjects: 0
Study 19778662 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of CRP
Number of subjects: 0
Study 19778662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers
Number of subjects: 0
Study 16453952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured sites (4‐0 nylon interrupted suture for 4‐mm lesions and two for 8‐mm lesions)
Number of subjects: 82
Study 16453952 — intervention group
Group type: COMPARATOR
Intervention: Secondary intention closure (gel foam applied for hemostasis)
Number of subjects: 82
Study 16453952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured sites (for 8‐mm punches)
Number of subjects: 82
Study 16453952 — intervention group
Group type: COMPARATOR
Intervention: Secondary intention closure (for 8‐mm punches)
Number of subjects: 82
Study 16453952 — intervention group
Group type: EXPERIMENTAL
Intervention: Both closure methods (for 4‐mm punches)
Number of subjects: 82
Study 15602019 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (60 microg/kg/day for 3 days before and after conditioning therapy)
Number of subjects: 212
Study 15602019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous for 3 days before and after conditioning therapy)
Number of subjects: 212
Study 15602019 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 212
Study 15602019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 11450818 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism
Number of subjects: 233
Study 11450818 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism/Information
Number of subjects: 233
Study 11450818 — intervention group
Group type: COMPARATOR
Intervention: No Autism
Number of subjects: 233
Study 11450818 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intentions (self)
Number of subjects: 233
Study 11450818 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intentions (others)
Number of subjects: 233
Study 11450818 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about autism
Number of subjects: 233
Study 9610075 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium gluconate (Mg-g) 648 mg elemental magnesium/day
Number of subjects: 47
Study 9610075 — intervention group
Group type: COMPARATOR
Intervention: Magnesium chloride (Mg-c) 640 mg elemental magnesium/day
Number of subjects: 47
Study 7923644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (0.6 mg/kg bolus followed by 0.2 mg/kg/hour infusion for 96 hours)
Number of subjects: 757
Study 7923644 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 U bolus and infusion of 1000 U/h for patients < 80 kg or 1300 U/h for patients >= 80 kg)
Number of subjects: 757
Study 7923644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 757
Study 7923644 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 757
Study 3352193 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise for 90 min
Number of subjects: 12
Study 3352193 — intervention group
Group type: COMPARATOR
Intervention: Interrupted exercise (5 min after each 25 min)
Number of subjects: 12
Study 3352193 — intervention group
Group type: COMPARATOR
Intervention: Intermittent physical activity
Number of subjects: 12
Study 31279641 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 positive patients with ≥ 1% PD-L1 staining
Number of subjects: 214
Study 31279641 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 positive patients with ≥ 50% PD-L1 staining
Number of subjects: 214
Study 31279641 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelioid MPM patients with high PD-L1 staining (≥ 50%)
Number of subjects: 214
Study 31279641 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low PD-L1 staining (< 50% cells)
Number of subjects: 214
Study 27045204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotics
Number of subjects: 249
Study 27045204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 249
Study 26147455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of autologous platelet-rich plasma (PRP) alone
Number of subjects: 68
Study 26147455 — intervention group
Group type: COMPARATOR
Intervention: Microdermabrasion alone
Number of subjects: 68
Study 26147455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intradermal PRP and microdermabrasion in the same session
Number of subjects: 68
Study 23237010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR); 2-hour sessions once a week for 10 weeks
Number of subjects: 55
Study 23237010 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 55
Study 23237010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR)
Number of subjects: 55
Study 21721071 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents (IPT‐A)
Number of subjects: 63
Study 21721071 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 63
Study 19196574 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐RITA group (n=45)
Number of subjects: 135
Study 19196574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid‐RITA group (n=45)
Number of subjects: 135
Study 19196574 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐RITA group (n=45)
Number of subjects: 135
Study 16526835 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention with low-fat diets and altered carbohydrate-to-protein ratio, specific details on dosage and duration not available.
Number of subjects: 0
Study 16526835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training, specific details on type and duration not available.
Number of subjects: 0
Study 16526835 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training, specific details on type and duration not available.
Number of subjects: 0
Study 16526835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diet and exercise programmes, specific details on type and duration not available.
Number of subjects: 0
Study 16526835 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet with high protein content, specific details on dosage and duration not available.
Number of subjects: 0
Study 15631970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy website (MoodGYM) - trial participants
Number of subjects: 19889
Study 15631970 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy website (MoodGYM) - public registrants
Number of subjects: 19889
Study 11208835 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant recombinant interferon alfa‐2b (rIFNalpha2b)
Number of subjects: 247
Study 11208835 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 247
Study 9667800 — intervention group
Group type: COMPARATOR
Intervention: Troglitazone 200 mg
Number of subjects: 0
Study 9667800 — intervention group
Group type: COMPARATOR
Intervention: Troglitazone 100 mg
Number of subjects: 0
Study 9667800 — intervention group
Group type: COMPARATOR
Intervention: Troglitazone 200-600 mg
Number of subjects: 0
Study 9667800 — intervention group
Group type: COMPARATOR
Intervention: Troglitazone (all doses)
Number of subjects: 0
Study 8164049 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative intraperitoneal chemotherapy with cisplatin
Number of subjects: 67
Study 8164049 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 67
Study 3066812 — intervention group
Group type: EXPERIMENTAL
Intervention: Keragen implant
Number of subjects: 130
Study 3066812 — intervention group
Group type: COMPARATOR
Intervention: Control (palliative care)
Number of subjects: 130
Study 31886854 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative screening for Staphylococcus aureus nasal carriers and selective 5-day decolonization using mupirocin ointment (experimental group).
Number of subjects: 534
Study 31886854 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo arm of the randomized Clinical Study).
Number of subjects: 534
Study 29324986 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1891
Study 29324986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1891
Study 27075577 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 pedicle screw fixation
Number of subjects: 140
Study 27075577 — intervention group
Group type: COMPARATOR
Intervention: Lateral mass screw fixation
Number of subjects: 140
Study 26564331 — intervention group
Group type: EXPERIMENTAL
Intervention: Citronella oil (100%) applied in indoor exposure test (N=101)
Number of subjects: 241
Study 26564331 — intervention group
Group type: EXPERIMENTAL
Intervention: Citronella oil (100%) applied in outdoor exposure test (N=140)
Number of subjects: 241
Study 26564331 — intervention group
Group type: COMPARATOR
Intervention: Control group in indoor exposure test (N=44)
Number of subjects: 241
Study 26564331 — intervention group
Group type: COMPARATOR
Intervention: Control group in outdoor exposure test (N=70)
Number of subjects: 241
Study 26564331 — intervention group
Group type: EXPERIMENTAL
Intervention: Citronella oil (100%) in outdoor exposure test
Number of subjects: 241
Study 26564331 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell satisfaction test (N=127)
Number of subjects: 241
Study 26564331 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritation level test (N=127)
Number of subjects: 241
Study 24251359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose edoxaban
Number of subjects: 21105
Study 24251359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose edoxaban
Number of subjects: 21105
Study 24251359 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 21905276 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR irradiation on each acupoint for 30 min, thrice a week, for two months
Number of subjects: 61
Study 21905276 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 61
Study 18188164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade treatment with candesartan (16 mg o.d.) and lisinopril (20 mg o.d.)
Number of subjects: 51
Study 18188164 — intervention group
Group type: COMPARATOR
Intervention: High-dose lisinopril (40 mg o.d.)
Number of subjects: 51
Study 18188164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade treatment with candesartan and lisinopril
Number of subjects: 51
Study 12059892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.1 mg/kg bolus followed by continuous infusion)
Number of subjects: 64
Study 9522671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clivarin 1750 (low-molecular heparin)
Number of subjects: 287
Study 9522671 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 2 x 500 mg (acetylsalicylic acid)
Number of subjects: 287
Study 7510063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation during pregnancy (treatment 3)
Number of subjects: 400
Study 7510063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation during pregnancy and the first 2 years of the child's life (treatment 4)
Number of subjects: 400
Study 7510063 — intervention group
Group type: COMPARATOR
Intervention: Sensory and developmental screening at ages 1 and 2 years (treatment 1)
Number of subjects: 400
Study 7510063 — intervention group
Group type: COMPARATOR
Intervention: Screening plus free transportation for prenatal and well‐child care (treatment 2)
Number of subjects: 400
Study 2518855 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms misoprostol h.s.
Number of subjects: 12
Study 2518855 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms misoprostol h.s.
Number of subjects: 12
Study 2518855 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol h.s.
Number of subjects: 12
Study 2518855 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms after supper
Number of subjects: 12
Study 2518855 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms misoprostol q.d.s.
Number of subjects: 12
Study 2518855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 796937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg/day
Number of subjects: 36
Study 796937 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 400 mg/day
Number of subjects: 36
Study 28209746 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (10 mg/kg IV) plus mFOLFOX-6 and bevacizumab (5 mg/kg IV)
Number of subjects: 194
Study 28209746 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX-6 and bevacizumab (5 mg/kg IV)
Number of subjects: 194
Study 28209746 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Number of subjects: 194
Study 26510086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin + Standard of Care (SOC) therapy (PEG-IFN/Ribavirin) for 48 weeks
Number of subjects: 60
Study 26510086 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) therapy (PEG-IFN/Ribavirin) for 48 weeks
Number of subjects: 60
Study 23588900 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm (fee displayed)
Number of subjects: 61
Study 23588900 — intervention group
Group type: COMPARATOR
Intervention: Control arm (fee not displayed)
Number of subjects: 61
Study 21606531 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 A/Indonesia/05/2005 vaccine (3.75 μg hemagglutinin antigen, AS03(A) adjuvanted)
Number of subjects: 4561
Study 21606531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4561
Study 19539098 — intervention group
Group type: EXPERIMENTAL
Intervention: InsuPatch device
Number of subjects: 17
Study 16670899 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 12